



RECEIVED  
DEC 12 2001  
TECH CENTER 1600/2900  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

|                        |   |                                   |
|------------------------|---|-----------------------------------|
| In re Application of:  | ) | For: N-Terminally Chemically      |
| Kinstler et al.        | ) | Modified Protein Compositions and |
|                        | ) | Methods                           |
| Serial No.: 09/309,217 | ) | Group Art Unit: 1648              |
| Filed: March 26, 2001  | ) | Examiner: Not yet assigned        |
|                        | ) |                                   |

TERMINAL DISCLAIMER

**Commissioner for Patents**  
**Washington, D.C. 20231**

Sir:

Amgen Inc., a Delaware Corporation having its principal place of business at 1840 Dehavilland Drive, Thousand Oaks, CA 91320-1789, is the assignee of the entire right, title, and interest in the above-identified patent application, and the assignee of United States Patent No. 5,824,784 as shown by the attached assignment.

Assignee hereby disclaims the terminal portion of the term of any patent granted on the above-identified application extending beyond the expiration date of United States Patent No. 5,824,784, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent and the legal title to United States Patent No. 5,824,784 are commonly owned, this agreement to run with any patent granted on the above-entitled application and to be binding upon assignee and its successors or assigns.

Assignee does not disclaim any terminal portion of the term of any patent granted on the above-identified application prior to the expiration date of the full statutory term of United States Patent No. 5,824,784, in the event that said Patent No. 5,824,784 later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or in part or is terminally disclaimed under 37 CFR 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to

12/11/2001 TGEDAMU1 00000020 09017725

01 FC:140

110.00 0P

expiration of its statutory term, except for the separation of legal title stated above.

The documents establishing the assignee's chain of title have been reviewed by the undersigned and the undersigned certifies that to the best of his/her knowledge and belief, title is in the assignee.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Amgen Inc.

By:



Mark H. Hopkins  
Reg. No. 44,775  
Agent for Applicants

Date: October 24, 2001